Bandingkan dokter dan harga Imunoterapi dengan Keytruda (Pembrolizumab) teratas di Israel. Temukan pencocokan terbaik Anda di sini.

Pilih negara dengan harga terbaik untuk layanan dokter

Bandingkan harga untuk Imunoterapi dengan Keytruda (Pembrolizumab) di negara-negara teratas

Ketuk negara untuk melihat dokter teratas dan harga

Turkey

Ukraine

South Korea

Mexico

Czech Republic

Canada

$3,300 - $10,000

$4,500 - $8,000

$5,200 - $8,500

$7,000 - $11,000

$7,500 - $10,500

$7,800 - $11,200

$2,000

$4,000

$6,000

$8,000

$10,000

$12,000

Dapatkan rencana perawatan yang dipersonalisasi gratis dan pilih opsi terbaik. Tanpa komitmen · Tidak ada pembayaran untuk layanan kami

Nir Peled

akreditasi:
Lokasi: Israel, Herzliya
Klinik:
4.0
Herzliya Medical Center
Spesialis terkemuka Israel dalam imunoterapi kanker paru-paru – Prof. Peled memimpin Unit Kanker Toraks di Pusat Kanker Davidoff.
- Pakar dalam Ilmu Penyakit Dalam, Pulmonologi, dan Onkologi Medis
- Penerima penghargaan ASCO MERIT untuk penelitian yang luar biasa
- Kepala Unit Penelitian dan Deteksi untuk Keganasan Toraks di Sheba Medical Center
- Ketua Komite Deteksi Dini & Pencegahan IASLC
Baca selengkapnya

Kunjungan dokter

Harga berdasarkan permintaan

Bookimed Insights: Spesialis Imunoterapi dengan Keytruda (Pembrolizumab) Teratas di Israel (2026)

Bookimed telah mengoordinasikan 15 permintaan untuk Imunoterapi dengan Keytruda (Pembrolizumab) di Israel, bekerja sama dengan 1 spesialis berperingkat tinggi. Dokter pada tabel ini dipilih berdasarkan kredensial internasional, keahlian klinis, dan hasil pasien. Peringkat 2026 disusun menggunakan data terverifikasi dari kasus pasien aktual dan program klinik mitra saat ini.

Peringkat	Dokter	pengalaman	Cocok Untuk	Apa yang Membedakan Mereka	Klinik & Lokasi	Konsultasi
#1	Nir Peled		Imunoterapi kanker paru	Pakar terkemuka dalam imunoterapi kanker paru-paru – memimpin unit penelitian utama dan menerima penghargaan ASCO MERIT. Ketua Komite Deteksi Dini IASLC.	Herzliya Medical Center Israel	Harga berdasarkan permintaan

FAQ

FAQ ini berasal dari pasien nyata yang mencari bantuan medis melalui Bookimed. Jawaban diberikan oleh koordinator medis berpengalaman dan perwakilan klinik terpercaya.

Which Israeli hospitals have the most active immunotherapy programs with Keytruda?

Sourasky Medical Center and Hadassah Medical Center lead Israel's immunotherapy landscape with extensive Keytruda programs. These institutions feature dedicated oncology divisions and specialized research units. They provide access to advanced protocols for melanoma, lung cancer, and gastrointestinal malignancies through international clinical trials and expert coordination.

Specialized oncology divisions: Sourasky (Ichilov) houses the first laboratory accredited for PD-L1 expression testing.
Gastrointestinal expertise: Dr. Auala Hubert at Hadassah leads immunotherapy for complex digestive system cancers.
Pediatric programs: Dana Dwek Children's Hospital at Sourasky offers specialized immunotherapy for pediatric oncology.
Advanced sarcoma treatment: Professor Ofer Merimsky pioneers Keytruda protocols for complex bone and soft tissue tumors.

Bookimed Expert Insight: Data shows that Sourasky Medical Center is a premier hub for complex cases due to its multi-disciplinary leadership. Dr. Ido Wolf chairs the National Council for Oncology, while Dr. David Sarid, trained at Oxford, leads clinical trials. This concentration of national leadership and international training allows patients to access treatment plans that align with the latest global standards.

Patient Consensus: Patients note that arriving with your own pathology slides can help avoid diagnostic delays in the busy Tel Aviv centers. Many describe a feeling of deep relief when accessing compassionate-use programs for advanced cancers in Jerusalem. Those who traveled to Israel emphasize that having a coordinator is vital to navigate the hospital bureaucracy quickly.

What criteria do Israeli doctors use to decide if a patient is eligible for Keytruda?

Israeli oncologists determine Keytruda eligibility by evaluating tumor biomarkers, specific cancer types, and previous treatment results. They prioritize genetic profiling and PD-L1 expression levels to confirm the therapy will be effective. Doctors also check if the patient meets the strict criteria outlined in the national health basket.

Biomarker testing: Doctors require evidence of PD-L1 expression, often at thresholds of 1% or 50%.
Genetic profiling: Eligibility often depends on Microsatellite Instability-High (MSI-H) or high Tumor Mutational Burden (TMB-H).
Cancer indications: Treatment is typically approved for advanced melanoma, non-small cell lung cancer, and HNSCC.
Treatment history: For some cancers, patients must first show resistance to standard chemotherapy or surgery.

Bookimed Expert Insight: Israeli specialists often combine clinical practice with genomic research to refine eligibility. For instance, Dr. Ari Raphael at Sourasky Medical Center serves as a principal investigator for Keytruda clinical trials. This dual role allows doctors to use NGS interpretation and T-cell studies to identify eligibility for patients who might not meet standard criteria. Consultations with experts like Dr. Irina Stepfansky, starting from $750, often include reviews of Phase I-III trial opportunities.

Patient Consensus: Patients note that having clear genetic test results like FoundationOne is essential to avoid treatment denials. They often describe a waiting period for committee approval but find that high PD-L1 levels speed up the process. Many are relieved that doctors also consider compassionate use for complex cases when standard benchmarks are not met.

Do the same doctors who prescribe Keytruda in Israel also handle side-effect management, or is care transferred?

Oncologists in Israel who prescribe Keytruda typically manage your entire treatment journey including side-effect monitoring. They remain your primary contact for evaluating blood work and symptoms before infusions. While they may consult sub-specialists for specific organ issues, the oncology team coordinates all corrective care.

Primary oversight: Prescribing oncologists like Dr. Pelles Sharon lead all initial side-effect assessments.
Specialist collaboration: Oncology teams consult internal endocrinologists or pulmonologists for immune-related reactions.
Patient alert cards: Israel uses standardized cards to help other doctors report reactions back to oncologists.
Continuous monitoring: Doctors at JCI-accredited centers like Sourasky manage fatigue, rashes, and digestive issues.

Bookimed Expert Insight: Data shows that top Israeli oncologists often hold dual research and clinical trial roles. For instance, Dr. David Sarid at Sourasky Medical Center is a principal investigator for clinical trials. This means these doctors often have earlier access to updated protocols for managing complex immunotherapy reactions before they become standard global practice.

Patient Consensus: Patients note their oncologists act as a central figure for infusions and monitoring without transferring care elsewhere. They appreciate that thyroid issues or rashes are handled within the same hospital system. Many feel this approach is much more organized than having to visit separate clinics for every side effect.

How can I compare Keytruda doctors in Israel if I only have virtual consultations available?

You can compare Keytruda doctors in Israel remotely by evaluating their clinical trial leadership, specialized fellowships, and hospital affiliations. Leading oncologists at JCI-accredited centers like Sourasky Medical Center offer video consultations to review genomic profiling and design personalized immunotherapy protocols before you travel.

Clinical trial leadership: Dr. Ari Raphael at Sourasky serves as a principal investigator for Keytruda trials.
International fellowship training: Prof. Ofer Merimsky completed advanced oncology training at Institut Gustave Roussy in Paris.
Sub-specialization focus: Dr. Pelles Sharon focuses on gastrointestinal tumors while Dr. Sonnenblick specializes in breast cancer.
Consultation accessibility: Top specialists provide virtual second opinions with fees ranging from $750 to $950.

Bookimed Expert Insight: Data shows a clear distinction between general oncologists and those leading Phase I-III immunotherapy trials. For complex cases, patients should prioritize doctors like Dr. Irina Stepfansky at Sourasky, who directs oncology hospitalization and manages high-level clinical research. These specialists often have earlier access to emerging combination protocols that general practitioners may not yet utilize.

Patient Consensus: Patients note it is helpful to ask doctors specific questions about how many Keytruda cycles they have managed for a particular cancer type. They suggest recording virtual sessions to compare the confidence and phrasing of different specialists side-by-side. Many felt more secure choosing doctors tied to major institutional centers like Hadassah or Sourasky due to their strict training standards.

Imunoterapi dengan Keytruda (Pembrolizumab) Dokter Terbaik di Herzliya - TOP-1 dokter

Dapatkan penawaran dari 3 spesialis Imunoterapi dengan Keytruda (Pembrolizumab) teratas di Israel